SARS-CoV-2 peptides and proteins with reduced adherence to Angiotensin Converting Enzyme-2

Patent number:

EP21382574.8

Reino de Navarra.svg
No items found.

The present invention refers to a mutated amino acid sequence, a mutated receptor-binding domain and a mutated Spike protein of SARS-CoV-2 with reduced adherence to Angiotensin Converting Enzyme-2 (ACE-2), antibodies that specifically binds to them, pharmaceutical and/or veterinary compositions comprising them, nucleic acids that encode them and therapeutic and prophylactic uses. In particular, the present invention refers to their uses in the prophylaxis and/or treatment of a SARS-CoV-2 infection and COVID disease.

Countries:
Spain
Regions:
Navarre
Centers:
UNIVERSIDAD PUBLICA DE NAVARRA
Other entities:
Navarrabiomed (Centro de Investigación Biomédica)
Sectors:
Health
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
BRL1: Hypothesizing on possible business concept
PDF Link:
Download here
Video Link:
Watch it here
Sustainable Development Goal:
SDG03: Good health and well-being
Applications

La variante del Spike de SARS-CoV-2 desarrollada preserva la mayor parte del sitio de unión a ACE-2, multiplica la concentración del inmunógeno en los nódulos linfáticos, aumenta el título de anticuerpos neutralizantes y reduce el potencial riesgo asociado al bloqueo de receptores ACE-2 debido a la propia vacunación. Mejora de la vacunación frente a SARS-CoV-2 y enfermedad COVID.

Comments

Other related patents

Health

NANOSYSTEMS WITH COMPLEXES

Countries
Spain
Know more
Health

CARBON NANOTUBE COATING FOR USE AS ANCHORING SYSTEM FOR NANOSCALE AND MICROMETRIC SCALE DEVICES WITH THERAPEUTIC ACTIVITY

Countries
Spain
Know more
Health

HANDLING OF MEMBRANE-SHAPED TISSUE

Countries
Belgium
Know more
Get back to patents directory